Vogenx Inc.(VOGX)

Biotechnology · Raleigh, NC

$16.39-0.76 (-4.43%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T21:08:46.087Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:08:46.087Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA: N/A
Quote market capitalization: 227,913,489
Total debt: N/A
Cash: N/A

FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

VOGX EBITDA Yield Metrics

EBITDA YIELD

N/A

VOGX Competitors' EBITDA Yield

VOGX

Vogenx Inc.

Current

Market Cap

$227.91M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BDSX

Biodesix, Inc.

vs VOGX

Market Cap

$227.60M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAUT

Nautilus Biotechnolgy, Inc.

vs VOGX

Market Cap

$225.24M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MGNX

MacroGenics, Inc.

vs VOGX

Market Cap

$231.37M

EBITDA Yield

N/A

TTM Avg

0.97%

3Y Avg

0.50%

5Y Avg

0.50%

GLSI

Greenwich LifeSciences, Inc.

vs VOGX

Market Cap

$231.77M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IFRX

InflaRx N.V.

vs VOGX

Market Cap

$232.72M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PROF

Profound Medical Corp.

vs VOGX

Market Cap

$220.93M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

UTMD

Utah Medical Products, Inc.

vs VOGX

Market Cap

$235.08M

EBITDA Yield

5.39%

TTM Avg

11.46%

3Y Avg

13.23%

5Y Avg

11.81%

AKBA

Akebia Therapeutics, Inc.

vs VOGX

Market Cap

$235.66M

EBITDA Yield

N/A

TTM Avg

6.75%

3Y Avg

3.64%

5Y Avg

3.64%

SIGA

SIGA Technologies, Inc.

vs VOGX

Market Cap

$235.97M

EBITDA Yield

N/A

TTM Avg

22.77%

3Y Avg

22.51%

5Y Avg

19.57%

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Vogenx Inc. (VOGX)	$227.91M	N/A	N/A	N/A	N/A
Biodesix, Inc. (BDSX)vs ›	$227.60M	N/A	N/A	N/A	N/A
Nautilus Biotechnolgy, Inc. (NAUT)vs ›	$225.24M	N/A	N/A	N/A	N/A
MacroGenics, Inc. (MGNX)vs ›	$231.37M	N/A	0.97%	0.50%	0.50%
Greenwich LifeSciences, Inc. (GLSI)vs ›	$231.77M	N/A	N/A	N/A	N/A
InflaRx N.V. (IFRX)vs ›	$232.72M	N/A	N/A	N/A	N/A
Profound Medical Corp. (PROF)vs ›	$220.93M	N/A	N/A	N/A	N/A
Utah Medical Products, Inc. (UTMD)vs ›	$235.08M	5.39%	11.46%	13.23%	11.81%
Akebia Therapeutics, Inc. (AKBA)vs ›	$235.66M	N/A	6.75%	3.64%	3.64%
SIGA Technologies, Inc. (SIGA)vs ›	$235.97M	N/A	22.77%	22.51%	19.57%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

VOGX EBITDA Yield Metrics

VOGX Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics